A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Summary: The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
clinicaltrials.gov

Short title: A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
clinicaltrials.gov

Official title: A Phase 2, Randomized, Triple-Blinded, Active-Controlled Study to Assess the Safety and Immunogenicity of an Investigational Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects ≥ 50 Years of Age
clinicaltrials.gov

Control arm: Active comparator
clinicaltrials.gov

Registry reports results: No
clinicaltrials.gov

Listing at source: Listed
clinicaltrials.gov

Recruitment status: Active, not recruiting
clinicaltrials.gov

Phase: Phase 2
clinicaltrials.gov

Study type: Interventional
clinicaltrials.gov

Completion date: 2026-08-01
clinicaltrials.gov

First posted: 2024-09-03
clinicaltrials.gov

Registry last updated: 2026-04-23
clinicaltrials.gov

Primary completion date: 2026-08-01
clinicaltrials.gov

Start date: 2024-10-16
clinicaltrials.gov

Actual participants: 467
clinicaltrials.gov

Participants: 467
clinicaltrials.gov

Participant count basis: Actual
clinicaltrials.gov

Protocol amendments: 2
clinicaltrials.gov

Randomisation ratio: 1:1
clinicaltrials.gov

Number of sites: 8
clinicaltrials.gov

Registry sponsor category: Industry
clinicaltrials.gov

Lead sponsor: Immorna Biotherapeutics, Inc.
clinicaltrials.gov

Source registry: ClinicalTrials.gov
clinicaltrials.gov

Registry ID: NCT06581575
clinicaltrials.gov

ClinicalTrials.gov ID: NCT06581575
clinicaltrials.gov

Registry record: Open registry record
clinicaltrials.gov

Allocation: Randomised
Model: Parallel groups
Purpose: Prevention
Masking: Quadruple masking
Masking description: Triple-blinded study
Masked roles: Participants, Care providers, Investigators, Outcome assessors

Sources for study design

clinicaltrials.gov

SAE Frequency
Timeframe: Day 1 - Day 241 (Week 34)
Frequency of SAEs characterized by type, severity, duration, and relationship to the vaccine recorded from Day 1 post-vaccine administration through follow-up completion.
Solicited local reaction frequency
Timeframe: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
Occurrence of solicited local injection site reactions characterize by frequency, severity, and duration within 7 days after each vaccine administration.
Solicited systemic reaction frequency
Timeframe: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
Occurrence of solicited systemic reactions characterize by frequency, severity, and duration within 7 days after each vaccine administration.
AE Frequency
Timeframe: Day 1 - Day 241 (Week 34)
Adverse events (AEs) including unsolicited AEs and any AEs leading to discontinuation of study vaccine or withdrawal from the study, characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion.
AESIs Frequency
Timeframe: Day 1 - Day 241 (Week 34)
AESIs characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion.
Medically Attended AE Frequency
Timeframe: Day 1 - Day 241 (Week 34)
Medically attended AEs (MAAEs) characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion.
Immune-Mediated Adverse Events of Special Interest Frequency
Timeframe: Day 1 - Day 241 (Week 34)
Immune-mediated adverse events of special interest (imAESIs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration through follow-up completion.
gE-Specific CD4+ T cell Response Rate
Timeframe: Day 1 - Day 89 (Week 13)
Response Rate is defined at the percentage of subjects with ≥ 2 folds increase of gE-specific CD4+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNFα, and CD40L) in PBMCs analyzed with flow cytometry with ICS on Day 89 as compared to baseline (Day 1 pre-dose).

Cellular immunogenicity of JCXH-105
Timeframe: Day 1 - Day 241 (Week 34)
Frequency of glycoprotein E (gE)-specific CD4+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNF-α, and CD40L) in PBMCs analyzed by flow cytometry with ICS on Day 29, Day 89, and Day 241 as compared to baseline (Day 1 pre-dose).

Sources for outcomes

clinicaltrials.gov

Sex: All
Age groups: Adults, Older adults
Minimum age: 50 Years
Healthy volunteers: Yes

Key Inclusion Criteria:

Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal.
Age: ≥ 50 years of age at screening.
Status: Healthy subjects.
Subjects must agree to not be vaccinated with any HZ vaccine while participating in this study.
Subjects must agree to not be vaccinated with any RNA-based vaccines (e.g., Spikevax, Comirnaty, etc.) 30 days before Dose 1 through 30 days after Dose 2 (a 4-month period).

Key Exclusion Criteria:

Subjects with a history of HZ within the past 10 years or current diagnosis of HZ.
Previous vaccination against HZ.
Subjects with any respiratory illness deemed clinically relevant by the Investigator within the past month OR hospitalization >24 hours for any reason within the past month prior to the first vaccine administration (JCXH-105 or Shingrix).
Subjects who are acutely ill or febrile with body temperature ≥ 38.0º Celsius/100.4º Fahrenheit 72 hours prior to or at the Screening visit or on Day 1 pre-dose. Subjects meeting this criterion may be rescheduled within an allowable window with approval from the Sponsor.
Subjects with history or current diagnosis of congenital or acquired immunodeficiency/immunocompromising/immunosuppressive conditions, asplenia, or recurrent severe infections. Certain immune-mediated conditions (e.g., Hashimoto thyroiditis) that are well controlled and stable are allowed.
Subjects with history of myocarditis or pericarditis, or with AEs (including anaphylaxis and severe hypersensitivity) after mRNA vaccination that are in nature and severity beyond the common expected AEs and necessitating medical intervention.
Subjects who received any non-live vaccine within 14 days prior to Day 1 (first dose of JCXH-105 or Shingrix).
Subjects who received within 28 days prior to Day 1 (first dose of JCXH-105 or Shingrix): (1) Any live vaccine, (2) Immunomodulators or immune-suppressive medication, (3) Granulocyte or granulocyte-macrophage colony-stimulating factor, (4) Three or more consecutive days of systemic corticosteroids. Note: subjects on stable-dose steroid replacement (for chronic disease such as iatrogenic deficiency) of prednisone ≤10 mg/day or equivalent are allowed and (5) Other investigational agents or devices.
Subjects receiving systemic antiviral therapy.
Subjects with a positive screening test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, anti-human HIV-1 and 2 antibodies, or syphilis.
Subjects with a positive screening test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).